Eravacycline Dihydrochloride Patent Expiration

Eravacycline Dihydrochloride is Used for treating complicated intra-abdominal infections in adults aged 18 years and older. It was first introduced by Tetraphase Pharmaceuticals Inc in its drug Xerava on Aug 27, 2018.


Eravacycline Dihydrochloride Patents

Given below is the list of patents protecting Eravacycline Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xerava US10961190 Crystalline forms of eravacycline Oct 19, 2037 Tetraphase Pharms
Xerava US11578044 Crystalline forms of eravacycline Oct 19, 2037 Tetraphase Pharms
Xerava US8906887 C7-fluoro substituted tetracycline compounds Dec 28, 2030 Tetraphase Pharms
Xerava US8796245 C7-fluoro substituted tetracycline compounds Aug 07, 2029 Tetraphase Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eravacycline Dihydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Eravacycline Dihydrochloride.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US8906887
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US8906887
Recordation of Patent Grant Mailed 14 Feb, 2023 US11578044
Patent Issue Date Used in PTA Calculation 14 Feb, 2023 US11578044
Email Notification 26 Jan, 2023 US11578044
Issue Notification Mailed 25 Jan, 2023 US11578044
Application Is Considered Ready for Issue 09 Jan, 2023 US11578044
Dispatch to FDC 09 Jan, 2023 US11578044
Supplemental Papers - Oath or Declaration 05 Jan, 2023 US11578044
Issue Fee Payment Verified 05 Jan, 2023 US11578044


Eravacycline Dihydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List